Michael Y Choi
University of California, San Diego
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Y Choi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:30 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT02860676 · Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961University of California, San Diego · completed · Chronic Lymphocytic Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:30 UTC. The ranking covers the 200 most relevant of 24 PubMed records, and a shared surname and initials can bring in a namesake. All 24 on PubMed
- Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.Lancet Oncol · 2017285 citationsRCR 9.1
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.J Clin Oncol · 2017248 citationsRCR 7.3
- Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.Cell Stem Cell · 2018177 citationsRCR 5.7
- A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.Ann Oncol · 2013116 citationsRCR 3.6
- 49 citationsRCR 1.9
- 36 citationsRCR 1.9
- Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies.Haematologica · 202236 citationsRCR 2.4
- Light and scanning electron microscopic evaluation of Glyde File Prep in smear layer removal.Int Endod J · 200332 citationsRCR 1.9
- A new subfascial approach in open thyroidectomy: efficacy for postoperative voice, sensory, and swallowing symptoms. A randomized controlled study.Ann Surg Oncol · 201332 citationsRCR 1.5
- Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome.Leuk Res · 201128 citationsRCR 0.8